Thus, by decreasing the concentration of active estrogens, an inhibitor of 17β-HSD1 activity could complement the use of an anti-estrogen (ER antagonist) in the treatment of breast cancer, as well as for the treatment of endometriosis. Here, ESR1 is linked to breast carcinoma.